Asia Deal Watch: SV Investment And Orange Grove Will Team Up On New Company Effort
Executive Summary
Takeda spins out Oak Hill Bio, Lupin and Axantia will co-develop filgrastim biosimilar and Xbiome licenses skin ulcer candidate from Aurealis.
You may also be interested in...
A Year And A Half After Giving Up On TAK-721, Takeda Seeks Approval In EoE
The US FDA rejected TAK-721 for eosinophilic esophagitis (EoE) in 2021, requiring another study, and Takeda ended development in 2022, but in a newly accepted NDA it is seeking a short-term treatment indication.
Finance Watch: VC Mega-Rounds Make A Comeback In March
Private Company Edition: After just seven venture capital rounds of $100m or more in January and February, five have been announced already in March, including a $200m series A round for Cargo Therapeutics, Chroma Medicine’s $135m series B financing and $112m for Noema’s series B.
Dr Reddy’s Brings In Range Of Mature Novartis Brands In India
With an ‘India First’ strategy previously communicated, Dr Reddy’s Laboratories has brought in several Novartis India Established Medicines. “We intend to evaluate capabilities to maintain business continuity,” the company says.